Who are Scholar Rock Holding Corporation's main suppliers?

Scholar Rock Holding Corporation (SRRK) key suppliers include: ADIMAB, Dyne Therapeutics, Inc., Keros Therapeutics, Inc.. View the full supplier network at chainsifter.com/chain/SRRK.

Who are Scholar Rock Holding Corporation's major customers?

Scholar Rock Holding Corporation (SRRK) key customers include: GILEAD, Dyne Therapeutics, Inc., Keros Therapeutics, Inc., Myriad Genetics, Inc., Myriad Genetics, Inc. and 7 more. View the full customer network at chainsifter.com/chain/SRRK.

What sector is Scholar Rock Holding Corporation in?

Scholar Rock Holding Corporation (SRRK) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Scholar Rock Holding Corporation Supplier List (SRRK): 3 Verified Suppliers

3Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Scholar Rock Holding Corporation (SRRK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

2Distinct source URLs

6High confidence

0.756Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Scholar Rock Holding Corporation Suppliers

Ticker	Name	Confidence	Evidence
ADIMAB	ADIMAB	80%	Under the Adimab Agreement, as amended, we selected a number of biological targets against which Adimab used its proprietary platform technology to discover and/or optimize antibodies
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
KROS	Keros Therapeutics, Inc.	72%	Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement…

Scholar Rock Holding Corporation Customers

Ticker	Name	Confidence	Evidence
GILEAD	GILEAD	90%	In connection with the Collaboration Agreement, we received an upfront payment of $50 million and an equity investment of $30 million
DYN	Dyne Therapeutics, Inc.	72%	Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
KROS	Keros Therapeutics, Inc.	72%	Reciprocal relationship from KROS graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS g…
MYGN	Myriad Genetics, Inc.	72%	rms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a 61 Table of C…
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from SRRK graph: rms and conditions of the proposed …
OBDC	Blue Owl Capital Corporation	72%	Reciprocal relationship from OBDC graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from SRRK graph: osses for the foreseeable future in…
OBDC	Blue Owl Capital Corporation	72%	osses for the foreseeable future in performing our ongoing activities, as we: ● develop our commercialization capabilities to support product sales, marketing and distribution activities; ● continue …
SNYNF	Sanofi	72%	rms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a 61 Table of C…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from SNYN…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, …
OXFORD-FINANCE-LLC	OXFORD-FINANCE-LLC	62%	osses for the foreseeable future in performing our ongoing activities, as we: ● develop our commercialization capabilities to support product sales, marketing and distribution activities; ● continue …
SILVERGATE-CAPITAL-CORP	SILVERGATE-CAPITAL-CORP	62%	services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, …

Scholar Rock Holding Corporation Debt Obligations

Instrument	Description	Confidence	Evidence
SRRK-DEBT	Debt stack $196.8M	90%	Market cache reports total debt of $196.8M.
SRRK-DEBT-12742	Warrants outstanding: 7614	90%	xbrl warrant detail from xbrl 2025-12-31.
SRRK-DEBT-12743	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2018-12-31.

Scholar Rock Holding Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Scholar Rock Holding Corporation.

Scholar Rock Holding Corporation Ownership

Holder	Name	Confidence	Evidence
SRRK-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 283 tracked holders.

Scholar Rock Holding Corporation Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
EDIT	Editas Medicine, Inc.	100.00	2
HTGC	Hercules Capital, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
BBIO	BridgeBio Pharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
PSNL	Personalis, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2

Scholar Rock Holding Corporation Supply Chain